Last reviewed · How we verify

Administration of Albendazole on Day 1

London School of Hygiene and Tropical Medicine · FDA-approved active Small molecule

Administration of Albendazole on Day 1 is a Benzimidazole anthelmintic Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently FDA-approved for Soil-transmitted helminth infections (roundworm, hookworm, whipworm), Lymphatic filariasis, Onchocerciasis (river blindness).

Albendazole inhibits microtubule polymerization in parasitic worms by binding to β-tubulin, disrupting their cellular structure and causing paralysis and death.

Albendazole inhibits microtubule polymerization in parasitic worms by binding to β-tubulin, disrupting their cellular structure and causing paralysis and death. Used for Soil-transmitted helminth infections (roundworm, hookworm, whipworm), Lymphatic filariasis, Onchocerciasis (river blindness).

At a glance

Generic nameAdministration of Albendazole on Day 1
SponsorLondon School of Hygiene and Tropical Medicine
Drug classBenzimidazole anthelmintic
Targetβ-tubulin
ModalitySmall molecule
Therapeutic areaInfectious Disease / Parasitology
PhaseFDA-approved

Mechanism of action

Albendazole is a benzimidazole anthelmintic that selectively binds to β-tubulin in nematodes and other helminths, preventing microtubule assembly and function. This disrupts glucose uptake and energy metabolism in the parasite, leading to immobilization and eventual death. The drug has selective toxicity for parasites over mammalian cells due to differential tubulin binding affinity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Administration of Albendazole on Day 1

What is Administration of Albendazole on Day 1?

Administration of Albendazole on Day 1 is a Benzimidazole anthelmintic drug developed by London School of Hygiene and Tropical Medicine, indicated for Soil-transmitted helminth infections (roundworm, hookworm, whipworm), Lymphatic filariasis, Onchocerciasis (river blindness).

How does Administration of Albendazole on Day 1 work?

Albendazole inhibits microtubule polymerization in parasitic worms by binding to β-tubulin, disrupting their cellular structure and causing paralysis and death.

What is Administration of Albendazole on Day 1 used for?

Administration of Albendazole on Day 1 is indicated for Soil-transmitted helminth infections (roundworm, hookworm, whipworm), Lymphatic filariasis, Onchocerciasis (river blindness), Cysticercosis, Echinococcosis.

Who makes Administration of Albendazole on Day 1?

Administration of Albendazole on Day 1 is developed and marketed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

What drug class is Administration of Albendazole on Day 1 in?

Administration of Albendazole on Day 1 belongs to the Benzimidazole anthelmintic class. See all Benzimidazole anthelmintic drugs at /class/benzimidazole-anthelmintic.

What development phase is Administration of Albendazole on Day 1 in?

Administration of Albendazole on Day 1 is FDA-approved (marketed).

What are the side effects of Administration of Albendazole on Day 1?

Common side effects of Administration of Albendazole on Day 1 include Abdominal pain, Diarrhea, Nausea, Headache, Dizziness, Elevated liver enzymes.

What does Administration of Albendazole on Day 1 target?

Administration of Albendazole on Day 1 targets β-tubulin and is a Benzimidazole anthelmintic.

Related